Literature DB >> 27240427

Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis.

Thomas Bahmer1, Anne-Marie Kirsten, Benjamin Waschki, Klaus F Rabe, Helgo Magnussen, Detlef Kirsten, Marco Gramm, Simone Hummler, Eva Brunnemer, Michael Kreuter, Henrik Watz.   

Abstract

BACKGROUND: Little is known about the consequences of idiopathic pulmonary fibrosis (IPF) for physical activity (PA).
OBJECTIVES: We aimed to investigate levels of PA in IPF and to study associations of PA with lung function, exercise capacity, symptoms, and quality of life.
METHODS: In stable patients with IPF we measured PA (steps per day, SPD; physical activity level, PAL; minutes of moderate activity, MMA) by accelerometry (SenseWear Armband) for 1 week. We also assessed lung function (forced vital capacity, FVC; diffusing capacity for carbon monoxide, DLCO); exercise capacity (6-minute walking distance, 6MWD); dyspnea (modified Medical Research Council, mMRC); fatigue (Multidimensional Fatigue Inventory, MFI-20), and generic (12-Item Short Form Survey, SF-12) and health-related quality of life (St. George's Respiratory Questionnaire) as further clinical variables.
RESULTS: We investigated 48 patients with IPF in two centers (mean age, 67 years; 75% male; 23% on long-term oxygen therapy; mean FVC 75%pred.; mean DLCO 43%pred.; mean 6MWD 355 ± 140 m; mean SPD 5,017 ± 3,360). On a bivariate level, all clinical variables were significantly associated with SPD (p < 0.05). The associations of mMRC, MFI-20, SF-12 (physical health), and 6MWD with SPD were independent of impaired lung function (p < 0.05). At multivariate analyses, either 6MWD (total explained variance of the model, total R2: 42%) or MFI-20 (total R2: 39%) were the strongest independent predictors of SPD.
CONCLUSION: Fatigue and exercise capacity are strong and independent predictors of PA in patients with IPF, which suggests that both measures should be assessed when the consequences of IPF for PA in daily life are studied.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27240427     DOI: 10.1159/000446607

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  17 in total

1.  Physical Activity and Fatigue in Patients with Sarcoidosis.

Authors:  Thomas Bahmer; Henrik Watz; Maria Develaska; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Anne-Marie Kirsten
Journal:  Respiration       Date:  2017-11-09       Impact factor: 3.580

2.  Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Authors:  Thomas Bahmer; Anne-Marie Kirsten; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Marco Gramm; Simone Hummler; Eva Brunnemer; Michael Kreuter; Henrik Watz
Journal:  BMC Pulm Med       Date:  2017-07-25       Impact factor: 3.317

3.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

Review 4.  Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Authors:  Paola Faverio; Marialuisa Bocchino; Antonella Caminati; Alessia Fumagalli; Monica Gasbarra; Paola Iovino; Alessandra Petruzzi; Luca Scalfi; Alfredo Sebastiani; Anna Agnese Stanziola; Alessandro Sanduzzi
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

5.  Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study.

Authors:  Marlies Wijsenbeek; Elisabeth Bendstrup; Claudia Valenzuela; Michael T Henry; Catharina Moor; Monica Bengus; Andras Perjesi; Frank Gilberg; Klaus-Uwe Kirchgaessler; Carlo Vancheri
Journal:  Adv Ther       Date:  2018-11-30       Impact factor: 3.845

6.  Severe Fatigue is Highly Prevalent in Patients with IPF or Sarcoidosis.

Authors:  Ada E M Bloem; Rémy L M Mostard; Naomi Stoot; Jan H Vercoulen; Jeannette B Peters; Daisy J A Janssen; Jan W H Custers; Martijn A Spruit
Journal:  J Clin Med       Date:  2020-04-20       Impact factor: 4.241

Review 7.  Managing Fatigue in Patients With Interstitial Lung Disease.

Authors:  Vivienne Kahlmann; Catharina C Moor; Marlies S Wijsenbeek
Journal:  Chest       Date:  2020-05-07       Impact factor: 9.410

8.  Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.

Authors:  Xue-Yan Yuan; Hui Zhang; Li-Ru Huang; Fan Zhang; Xiao-Wen Sheng; Ai Cui
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

9.  Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients.

Authors:  Benoit Wallaert; Nicolas Masson; Olivier Le Rouzic; Baptiste Chéhère; Lidwine Wémeau-Stervinou; Jean-Marie Grosbois
Journal:  ERJ Open Res       Date:  2018-06-11

Review 10.  Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.

Authors:  Toby M Maher; Mary E Strek
Journal:  Respir Res       Date:  2019-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.